The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.

2.50
Hdl Handle:
http://hdl.handle.net/2436/14650
Title:
The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
Authors:
Bates, Ruth L.; Payne, Sarah J.; Drury, S.L.; Nelson, Paul N.; Isenberg, D.A.; Murphy, John J.; Frampton, Geoffrey
Abstract:
We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.
Citation:
Lupus 2003, 12(8): 617-622
Publisher:
SAGE Publications
Issue Date:
2003
URI:
http://hdl.handle.net/2436/14650
DOI:
10.1191/0961203303lu436oa
PubMed ID:
12945721
Additional Links:
http://lup.sagepub.com/cgi/content/abstract/12/8/617; http://direct.bl.uk/bld/PlaceOrder.do?UIN=136076849&ETOC=RN&from=searchengine
Type:
Article
Language:
en
Description:
Metadata record only
ISSN:
0961-2033
Appears in Collections:
Molecular Immunology Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorBates, Ruth L.-
dc.contributor.authorPayne, Sarah J.-
dc.contributor.authorDrury, S.L.-
dc.contributor.authorNelson, Paul N.-
dc.contributor.authorIsenberg, D.A.-
dc.contributor.authorMurphy, John J.-
dc.contributor.authorFrampton, Geoffrey-
dc.date.accessioned2007-11-19T12:46:03Z-
dc.date.available2007-11-19T12:46:03Z-
dc.date.issued2003-
dc.identifier.citationLupus 2003, 12(8): 617-622en
dc.identifier.issn0961-2033-
dc.identifier.pmid12945721-
dc.identifier.doi10.1191/0961203303lu436oa-
dc.identifier.urihttp://hdl.handle.net/2436/14650-
dc.descriptionMetadata record onlyen
dc.description.abstractWe have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.en
dc.language.isoenen
dc.publisherSAGE Publicationsen
dc.relation.urlhttp://lup.sagepub.com/cgi/content/abstract/12/8/617en
dc.relation.urlhttp://direct.bl.uk/bld/PlaceOrder.do?UIN=136076849&ETOC=RN&from=searchengine-
dc.subjectSystemic lupus erythematosusen
dc.subjectAutoantigenen
dc.subjectSLEen
dc.subjectAnti-PAI-1en
dc.titleThe prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.